Stephens downgraded Centene to Equal Weight from Overweight with a price target of $85, down from $92. The business and stock performance have been “firmly locked into a largely repetitive ‘one-step forward, one-step back’ cycle” over the past two years, says the analyst, who adds that the disappointing Texas STAR and CHIP Medicaid RFP outcome “continued this trend into 2024.” This has created a more “asymmetrically negative” near-term setup into the pending Florida and Georgia RFP announcements, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CNC:
- Centene to Reaffirm 2024 Earnings Guidance at Barclays Conference
- Barclays starts health care facilities, managed care group with Neutral view
- Centene initiated with an Overweight at Barclays
- Centene files automatic mixed securities shelf
- Centene price target lowered to $81 from $82 at Deutsche Bank
